MY199248A - Vaccination with mica/b alpha 3 domain for the treatment of cancer - Google Patents

Vaccination with mica/b alpha 3 domain for the treatment of cancer

Info

Publication number
MY199248A
MY199248A MYPI2018000849A MYPI2018000849A MY199248A MY 199248 A MY199248 A MY 199248A MY PI2018000849 A MYPI2018000849 A MY PI2018000849A MY PI2018000849 A MYPI2018000849 A MY PI2018000849A MY 199248 A MY199248 A MY 199248A
Authority
MY
Malaysia
Prior art keywords
alpha
domain
cancer
vaccination
mica
Prior art date
Application number
MYPI2018000849A
Other languages
English (en)
Inventor
Kai Wucherpfennig
Soumya Badrinath
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of MY199248A publication Critical patent/MY199248A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MYPI2018000849A 2015-12-04 2016-12-05 Vaccination with mica/b alpha 3 domain for the treatment of cancer MY199248A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263377P 2015-12-04 2015-12-04
US201662422454P 2016-11-15 2016-11-15
PCT/US2016/064969 WO2017096374A1 (en) 2015-12-04 2016-12-05 Vaccination with mica/b alpha 3 domain for the treatment of cancer

Publications (1)

Publication Number Publication Date
MY199248A true MY199248A (en) 2023-10-23

Family

ID=57590885

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018000849A MY199248A (en) 2015-12-04 2016-12-05 Vaccination with mica/b alpha 3 domain for the treatment of cancer

Country Status (24)

Country Link
US (3) US10993971B2 (cg-RX-API-DMAC7.html)
EP (1) EP3383426A1 (cg-RX-API-DMAC7.html)
JP (3) JP7099956B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180088458A (cg-RX-API-DMAC7.html)
CN (1) CN108770343A (cg-RX-API-DMAC7.html)
AU (3) AU2016362597C1 (cg-RX-API-DMAC7.html)
BR (1) BR112018010705A8 (cg-RX-API-DMAC7.html)
CA (1) CA3005910A1 (cg-RX-API-DMAC7.html)
CL (3) CL2018001470A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018006642A2 (cg-RX-API-DMAC7.html)
CR (2) CR20180350A (cg-RX-API-DMAC7.html)
CU (2) CU20210061A7 (cg-RX-API-DMAC7.html)
EA (1) EA201891287A1 (cg-RX-API-DMAC7.html)
IL (1) IL259490A (cg-RX-API-DMAC7.html)
MX (2) MX2018006785A (cg-RX-API-DMAC7.html)
MY (1) MY199248A (cg-RX-API-DMAC7.html)
NZ (1) NZ742663A (cg-RX-API-DMAC7.html)
PE (2) PE20181158A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018501170A1 (cg-RX-API-DMAC7.html)
RU (2) RU2021109510A (cg-RX-API-DMAC7.html)
SG (1) SG11201804597TA (cg-RX-API-DMAC7.html)
TN (1) TN2018000187A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017096374A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202204223B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021519599A (ja) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ 抗原性ｏｓｐａポリペプチド
KR20210018206A (ko) 2018-04-03 2021-02-17 사노피 항원성 호흡기 세포융합 바이러스 폴리펩타이드
WO2019195316A1 (en) 2018-04-03 2019-10-10 Sanofi Ferritin proteins
JP7614842B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性エプスタインバーウイルスポリペプチド
EP4110384A4 (en) * 2020-02-26 2024-07-31 The Wistar Institute of Anatomy and Biology COMPOSITIONS CONTAINING SELF-ASSEMBLING VACCINES AND METHODS OF USE THEREOF
AU2021305084A1 (en) 2020-07-07 2023-02-02 Cancure, Llc MIC antibodies and binding agents and methods of using the same
CN116396398B (zh) * 2023-01-16 2024-07-16 四川大学 一种实现铁蛋白纳米颗粒可控自组装的方法以及基于该方法搭建的纳米颗粒抗原展示平台
WO2024222886A1 (zh) * 2023-04-28 2024-10-31 北京先声祥瑞生物制品股份有限公司 一种针对MICA/B靶点的mRNA肿瘤疫苗

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
ES2130265T3 (es) 1992-05-06 1999-07-01 Harvard College Region de union al receptor de la toxina difterica.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
DE69739981D1 (de) 1996-10-31 2010-10-14 Human Genome Sciences Inc Streptococcus pneumoniae-Antigene und Impfstoffe
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
ES2307093T3 (es) 2001-10-01 2008-11-16 THE GOVERNMENT OF THE USA, AS REPR. BY SECRETARY, DEPT. HEALTH & HUMAN SERVICES, NAT. INST OF HEALTH Desarrollo de un vacuna preventiva para la infeccion por filovirus en primates.
US6706305B2 (en) 2001-10-31 2004-03-16 Conagra Foods Inc. Low glycemic index bread
AU2003228962A1 (en) 2002-05-10 2003-11-11 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
AU2005302291B2 (en) 2004-11-02 2011-02-10 The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CA2665090A1 (en) 2006-09-22 2008-03-27 Dana-Farber Cancer Institute, Inc. Methods for treating mica-related disorders
US8182809B1 (en) * 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
US20120269721A1 (en) 2009-10-12 2012-10-25 The Regents Of The University Of California Targeted nanoclusters and methods of their use
WO2011074573A1 (ja) 2009-12-18 2011-06-23 花王株式会社 メソポーラスシリカ粒子の製造方法
JP5603063B2 (ja) 2009-12-21 2014-10-08 花王株式会社 複合シリカ粒子の製造方法
RU2489169C2 (ru) * 2010-10-12 2013-08-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Способ лечения онкологических заболеваний
CA2849374A1 (en) * 2011-09-23 2013-03-28 University Of Oslo Vaccibodies targeted to cross-presenting dendritic cells
ES2757473T3 (es) 2011-09-30 2020-04-29 Dana Farber Cancer Inst Inc Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA)
US10577416B2 (en) 2012-02-07 2020-03-03 Innate Pharma, S.A. Mica binding agents
LT2838515T (lt) 2012-04-16 2020-03-10 President And Fellows Of Harvard College Mezoporinės silico dioksido kompozicijos, skirtos imuninio atsako moduliavimui
CN105142668B (zh) 2013-03-15 2018-04-27 达纳-法伯癌症研究院公司 治疗性肽
CA2906356A1 (en) * 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
AU2015229009B2 (en) * 2014-03-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring NKG2D pathway function against cancers

Also Published As

Publication number Publication date
PH12018501170A1 (en) 2019-01-21
CL2021001256A1 (es) 2021-12-31
BR112018010705A2 (pt) 2018-11-21
SG11201804597TA (en) 2018-06-28
JP2022130623A (ja) 2022-09-06
US20180353581A1 (en) 2018-12-13
CN108770343A (zh) 2018-11-06
BR112018010705A8 (pt) 2019-02-26
IL259490A (en) 2018-07-31
CU24609B1 (es) 2022-06-06
RU2018123307A3 (cg-RX-API-DMAC7.html) 2020-04-20
RU2021109510A (ru) 2021-04-16
CU20210061A7 (es) 2022-02-04
NZ742663A (en) 2023-02-24
TN2018000187A1 (en) 2019-10-04
CL2018001470A1 (es) 2018-12-21
AU2016362597C1 (en) 2022-05-26
US20250064863A1 (en) 2025-02-27
US20210299186A1 (en) 2021-09-30
JP2018536002A (ja) 2018-12-06
MX2018006785A (es) 2018-11-09
CO2018006642A2 (es) 2018-07-10
CU20180050A7 (es) 2018-11-06
RU2018123307A (ru) 2020-01-13
KR20180088458A (ko) 2018-08-03
WO2017096374A1 (en) 2017-06-08
AU2022201940A1 (en) 2022-04-14
CR20230116A (es) 2023-05-05
ZA202204223B (en) 2023-12-20
RU2747296C2 (ru) 2021-05-04
CR20180350A (es) 2018-10-02
US10993971B2 (en) 2021-05-04
EP3383426A1 (en) 2018-10-10
CA3005910A1 (en) 2017-06-08
PE20230495A1 (es) 2023-03-23
AU2016362597A1 (en) 2018-06-07
EA201891287A1 (ru) 2018-11-30
JP2024177207A (ja) 2024-12-19
PE20181158A1 (es) 2018-07-19
CL2023003217A1 (es) 2024-06-28
AU2025213685A1 (en) 2025-08-28
AU2022201940B2 (en) 2025-05-08
JP7099956B2 (ja) 2022-07-12
MX2022010194A (es) 2022-09-19
JP7564842B2 (ja) 2024-10-09
AU2016362597B2 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
ZA202204223B (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
ZA201903327B (en) Compositions and methods for the induction of cd8+ t¿cells
MX2017005325A (es) Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
NZ731467A (en) Anti-tim3 antibodies and methods of use
SG10201903349YA (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2016011114A (es) Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
SG10201808278TA (en) Polishing composition and polishing method
MX2018011875A (es) Reprogramacion cardiaca directa mejorada.
WO2015139020A3 (en) Vaccine compositions and methods for restoring nkg2d pathway function against cancers
PH12016501838A1 (en) Compounds and their methods of use
BR112019004102A2 (pt) imunoterapia para poliomavírus
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX2018015431A (es) Composicion cosmetica anti-signos, uso de la composicion, metodo de tratamiento anti-signos y dispositivo aplicador.
HK1262082A1 (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
HK1242965A1 (en) Apilimod for use in the treatment of colorectal cancer
HK1232563A1 (en) Compositions and methods for the treatment of her2/neu over-expressing tumors